New virtual incubator puts all the pieces together to speed therapies to market

摘要

It was both the need and opportunity to provide funding and resources to very early stage research that prompted the formation of a new virtual incubator - Autobahn Labs. The incubator is using a new and comprehensive model of support for early-stage drug innovations, combining a typical incubator's help with VC deep pockets and a pharma company's deep expertise. And it's partnering with university TTOs to gain access to their most promising pharma innovations. At the heart of this new entity, which officially launched in June, are investment firms Samsara BioCapital and KCK, as well as Evotec, a drug discovery and development company.